MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

    L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

    Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…
  • 2016 International Congress

    Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

    M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

    Objective: Taking into account the background of our research group and the knowledge that MAO and ChE activity generates ROS that cause neuronal cell death,…
  • 2016 International Congress

    Drug safety in the pharmacotherapy of Parkinson’s disease

    S. Müller-Rebstein, C. Trenkwalder, J. Ebentheuer, C. Culmsee, G. Höglinger (Kassel, Germany)

    Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…
  • 2016 International Congress

    Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study

    C. Stuijt, T.V. Laar (Groningen, Netherlands)

    Objective: Improvement of on-off symptoms in ambulatory patients with Parkinson's disease (PD) by introduction of a multi-faceted medication optimization program. This consisted of a patient…
  • 2016 International Congress

    Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients

    M. Zibetti, S. Angrisano, F. Dematteis, A. Romagnolo, A. Merola, L. Lopiano (Torino, Italy)

    Objective: To determine whether levodopa-carbidopa intestinal gel (LCIG) infusion is able to improve freezing of gait (FOG) in advanced Parkinson's disease (PD) patients. Background: FOG…
  • 2016 International Congress

    Use of nicotine gum to treat acute low blood pressure in Parkinson’s disease

    J. DiFrancisco-Donoghue, A. Leder, M.K. Jung, W.G. Werner (Old Westbury, NY, USA)

    Objective: To evaluate (1) how nicotine chewing gum is tolerated (2) how nicotine chewing gum affects acute low blood pressure (BP) in Parkinson's disease (PD).…
  • 2016 International Congress

    A phase II, pragmatic, randomized clinical trial on a high-intensity exercise and fall prevention boot camp for Parkinson’s disease: Feasibility and safety

    M.R. Landers, J.W. Navalta (Las Vegas, NV, USA)

    Objective: To test the feasibility and safety of a high-intensity exercise and fall prevention boot camp (HIBC) in people with Parkinson's disease (PD). Background: Most…
  • 2016 International Congress

    VANTAGE trial: Three year outcomes of a prospective, multi-center trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease

    L. Timmerman, R. Jain, L. Chen, T. Brucke, F. Seijo, E. Suarez San Martin, C. Haegelen, M. Verin, V. Visser-Vandewalle, M.T. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Cologne, Germany)

    Objective: The VANTAGE study assesses motor improvement in moderate-to-severe Parkinson's disease (PD) following bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) using a new, implantable,…
  • 2016 International Congress

    Duodenal levodopa infusion: Safety and efficacy in a 6 years outpatient follow-up

    S. Simoni, N. Tambasco, E. Sacchini, P. Nigro, F. Ripandelli, P. Calabresi (Perugia, Italy)

    Objective: To reduce the risk of adverse events and dropout rate in patients. Background: Duodenal levodopa infusion (DLI) is used for the treatment of advanced…
  • 2016 International Congress

    Patient experiences following Parkinson’s disease treatment with inhaled levodopa: Results from a Phase 2b study

    P. LeWitt, A. Niyazov, A. Sedkov, H. Murck, A. Guo (West Bloomfield, MI, USA)

    Objective: To report patient experiences from a clinical trial investigating Parkinson's disease (PD) control following treatment with inhaled levodopa. Background: CVT-301, an inhaled levodopa powder…
  • « Previous Page
  • 1
  • …
  • 62
  • 63
  • 64
  • 65
  • 66
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley